By Allison DeAngelis, Adam Feuerstein, and Elaine Chen

Sept. 19, 2024

Are generalist investors good or bad for biotech? How did Elaine and Adam’s trip to New York go? And how long has George Church owned that brown corduroy blazer?

We cover all that and more on the latest episode of “The Readout Loud.” Mizuho analyst Jared Holz joins us to discuss what the Federal Reserve’s long-awaited decision to lower interest rates means for biotech stocks and startups. Elaine, Adam, and Allison also discuss the latest news in life sciences, including the use of cannabinoid receptor drugs in weight loss and the Lasker Awards, a.k.a. “America’s Nobel.”

advertisement

For more on Novo Nordisk and Corbus Pharmaceuticals’ CB1 work, go here; for more on the Lasker Award recipients, click here; for more on Applied Therapeutics’ cancelled Food and Drug Administration meeting, click here; and to learn more about George Church’s new startup, go here.

Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

, , ,
Submit a correction requestReprints

  1. Allison DeAngelis

    Biotech Startups and Venture Capital Reporter

    Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

  2. Adam Feuerstein

    Senior Writer, Biotech

    Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard.

  3. Elaine Chen

    National Biotech Reporter

    Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud.